Company: IONQ
Filing Date: 2025-02-27
Form Type: 424B5
Source: 0001193125-25-037295
Chunk: 7

Company: IonQ, Inc.
Filing Date: 2025-02-27
Form: 424B5
Chunk 7
---
 offering in a manner that does not produce income or that loses value.

If you purchase our common stock in this offering, you may experience immediate and substantial dilution in the net tangible book value of your shares.

The offering price per share
in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming that an aggregate of 16,818,028 shares of our common stock are sold at a price of $29.73 per share, the last reported
sale price of our common stock on the New York Stock Exchange on February 25, 2025, for aggregate gross proceeds of $500 million, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate dilution
of $26.26 per share, representing the difference between our as adjusted net tangible book value per share as of December 31, 2024 after giving effect to this offering and the assumed public offering price. The exercise of outstanding stock
options would result in further dilution of your investment. See the section titled “Dilution” below for a more detailed illustration of the dilution you would incur if you participate in this offering. Because the sales of the shares
offered hereby will be made directly into the market or in negotiated transactions, the prices at which we sell these shares will vary and these variations may be significant. Purchasers of the shares we sell, as well as our existing stockholders,
will experience significant dilution if we sell shares at prices significantly below the price at which they invested.

Future sales or issuances of our common stock in the public markets, including sales by our directors and officers, or the perception of such sales, could depress the trading price of our common stock.

The sale of a substantial number of shares of our common stock or other equity-related securities in the public markets, or the perception that such sales
could occur, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We may sell large quantities of our common stock at any time pursuant to this prospectus
supplement or in one or more separate offerings. In addition, our directors and officers are not subject to any “lock-up” or other agreements with our sales agents

S-4

restricting them from selling shares of common stock during or in connection with the offer and sale of shares of our common stock pursuant to this prospectus supplement, and accordingly, subject
to securities law restrictions, our directors and